Abstract
Oral route of drug administration remains the most favored preference for majority of therapeutic application, with obvious advantages including ease of administration, patient compliance and flexibility in formulation. Numerous oral controlled release the drug at a predetermined, predictable rate and also optimize the therapeutic effect by controlling the drug release. However this approach is be ditched with several physiological difficulties such as inability to restrain and localize the drug delivery system within the desired region of the gastrointestinal tract due to variable gastric emptying and motility. Gastric emptying time in humans results in an incomplete drug release from controlled DDS. The ability of a dosage form to prolong and control the gastric emptying time is a valuable asset for drug acting locally in GIT. These considerations led to the development of gastro retentive dosage forms increase they one of the most feasible approaches for achieving a prolonged and predictable drug delivery profiles in the GIT is to control the gastric residence time, using gastro retentive dosage form that will provide us with new and therapeutic option Oflaxacin polymers and gums like guargum, xanthangum other than HPMC in different concentration. Tablets were compressed and In-vitro and in-vivo release profile. Prevent study involves an overview formulation and evaluation of FDDS for a prolonged and predictable and HPMC with swellable polymers.
